The Quiet Exit From Independent Practice
Pulmonologists built their practices over decades – managing complex respiratory conditions, navigating insurance bureaucracies, and serving patient populations that increasingly skew older and sicker. Now, a growing number of those same physicians are signing letters of intent with private equity-backed management companies, taking liquidity events, and staying on as employed physicians under new ownership structures they did not design. The transition is happening fast enough that many patients won’t notice until a billing statement arrives from an unfamiliar entity.
Pulmonology sits in a particularly attractive position for PE rollup strategy. The specialty has strong recurring revenue from chronic disease management – COPD, asthma, pulmonary fibrosis, sleep-disordered breathing – and a patient base that returns regularly rather than episodically. That predictability is exactly what acquisition models depend on when projecting cash flow across a platform of consolidated practices.
Why Pulmonology, Why Now
The demographics driving demand for respiratory care are not slowing down. An aging population, persistent rates of smoking-related lung disease, post-viral respiratory complications, and rising air quality concerns in urban and industrial corridors have all expanded the pool of patients requiring specialist care. For PE-backed platforms building out healthcare portfolios, a specialty with built-in demand growth is more attractive than one dependent on elective procedures or seasonal patterns.
Independent pulmonology groups also tend to run lean – a small number of physicians sharing back-office functions, billing staff, and clinical support. That structure creates immediate margin expansion opportunities for an acquirer willing to centralize administration, renegotiate supplier contracts, and push ancillary revenue streams like in-office pulmonary function testing, sleep studies, and bronchoscopy suites. The operational upside is visible before the deal closes.
Physician fatigue is doing a significant portion of the recruiting work. Credentialing requirements, prior authorization burdens, and the administrative weight of running a small business have worn down physicians who entered the specialty to practice medicine, not manage billing denials. A PE offer that includes a liquidity event, a management team to handle operations, and a continued clinical role looks attractive to a physician in their late 40s or early 50s who has no obvious succession plan and no appetite to train one up from within the practice.
How the Rollup Model Actually Works
The acquisition structure typically involves a platform company – often seeded by a PE firm – that purchases an initial “anchor” practice, then uses that base to acquire additional regional groups under a shared brand or management services organization. The acquiring entity handles billing, human resources, contracting, and capital expenditures. The physicians retain some form of clinical autonomy, at least in early stages, and receive equity in the broader platform alongside their cash payment at close.
That equity component matters because it shapes physician behavior post-acquisition. Physician-owners who receive platform equity have a financial incentive to support growth, recruit peers into the fold, and hit productivity targets that increase the platform’s valuation ahead of a secondary sale – typically to a larger PE fund or a strategic acquirer like a hospital system. The rollup is not the end state. It is a vehicle for the next transaction.
The Compression Points Nobody Discusses at the Letter of Intent Stage
The pressure on clinical operations typically begins appearing 12 to 18 months after a deal closes. Patient volume targets increase. Appointment slots tighten. Ancillary services that were once discretionary become revenue expectations embedded in quarterly performance reviews. Physicians who accepted the deal expecting preserved autonomy find themselves negotiating with a regional medical director they did not hire and cannot remove.
Staffing ratios are a consistent friction point. Centralized management structures often reduce support staff per physician in the name of efficiency, which shifts administrative burden back onto clinical staff. A pulmonologist who previously had a dedicated medical assistant and a nurse practitioner supporting the panel may find those resources pooled across a larger group, with response times and workflow continuity suffering as a result. Patients with complex respiratory conditions – the kind requiring careful titration of inhaled therapies and close monitoring – feel that degradation acutely.
Payer contracting is another area where the platform’s interests and the individual physician’s interests diverge. Centralized contracting can improve negotiated rates in some markets, but it can also make participation in certain Medicaid or underserved-market programs economically inconvenient for a platform trying to optimize EBITDA. Regional home health billing groups have already navigated the political difficulty of exiting Medicaid contracts when the math stops working – pulmonology platforms face the same calculus, with the same consequences for lower-income patient populations.
The physicians who fare best inside these structures tend to be those who negotiated contract protections before signing – guaranteed base compensation for a defined period, explicit protections against unilateral reduction of clinical support staff, and clear language around what triggers a non-compete. Those terms are available but not automatic. A physician walking into a PE acquisition without healthcare transaction counsel is accepting whatever the platform’s form documents say, and those documents are written in the platform’s interest, not the physician’s.
Frequently Asked Questions
Why are private equity firms targeting pulmonology practices?
Pulmonology offers predictable recurring revenue from chronic conditions like COPD and asthma, an aging patient base, and operational inefficiencies that PE platforms can consolidate for margin gains.
What happens to physicians after a PE acquisition closes?
Physicians typically remain as employed clinicians, often receiving platform equity, but face increasing volume targets and reduced administrative autonomy within 12 to 18 months of the deal closing.
